JG
SCMP

Joel Greenblatt’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Joel Greenblatt’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-39,830
Closed -$470K – 1125
2017
Q3 		$470K Sell
39,830
-46,137
-54% -$518K 0.01% 712
2017
Q2 		$903K Sell
85,967
-133,949
-61% -$1.37M 0.01% 651
2017
Q1 		$2.42M Buy
219,916
+164,408
+296% +$1.91M 0.03% 523
2016
Q4 		$752K Buy
+55,508
New +$774K 0.01% 671
2016
Q2 		– Sell
-284,704
Closed -$3.11M – 1161
2016
Q1 		$3.11M Sell
284,704
-299,012
-51% -$3.78M 0.03% 513
2015
Q4 		$10.1M Buy
583,716
+427,511
+274% +$7.66M 0.11% 286
2015
Q3 		$3.1M Sell
156,205
-178,141
-53% -$4.08M 0.03% 487
2015
Q2 		$5.49M Buy
334,346
+230,808
+223% +$4M 0.05% 435
2015
Q1 		$1.61M Buy
+103,538
New +$1.61M 0.01% 542

Other funds holding SCMP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Joel Greenblatt's SCMP Position: Q4 2017 in Review

Joel Greenblatt sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q4 2017, closing a stake of 39,830 shares — an estimated $470K sold.

Joel Greenblatt first reported a position in SCMP in Q1 2015 and held it in 9 quarters. The position peaked at $10.1M in Q4 2015. 188 funds tracked by Wall St. Rank hold SCMP as of Q4 2017.

  • Joel Greenblatt reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Joel Greenblatt sold 39,830 Sucampo Pharmaceuticals, Inc. shares in Q4 2017, an estimated $470K.
  • Joel Greenblatt first reported a position in Sucampo Pharmaceuticals, Inc. in Q1 2015 and held it in 9 quarters.
  • Joel Greenblatt's Sucampo Pharmaceuticals, Inc. position peaked at $10.1M in Q4 2015.
  • 188 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q4 2017.

Based on Gotham Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.